Bengaluru-based LiteFold, founded in 2025, launched an AI "co-scientist" platform named Rosalind for drug discovery. This platform targets a critical bottleneck: computational biologists spending more time building software than solving biological problems. For biotech R&D teams, it promises to run hundreds of hypotheses in parallel, drastically cutting development cycles.
How We Got Here
Co-founder Anindyadeep Sannigrahi, an ML engineer, started building an "IDE for computational biologists" during his 2025 AI residency at Lossfunk in Bengaluru. He then partnered with US-based computational biologist Cory Kornowicz, who joined LiteFold after seeing Sannigrahi's project on X.
The Numbers
- The Nobel Prize for computational protein design was awarded in 2024, a year before Sannigrahi joined Lossfunk.
- LiteFold’s five-member team operates out of Bengaluru, India, and Delaware, US.
- Its Rosalind platform currently focuses on therapeutic design, with plans to expand into biological engineering.
- The platform integrates AI workflows to legal processes, intentionally excluding resource-intensive wet lab testing.
What Happens Next
🇮🇳 Why This Matters for India
For Bangalore-based deep tech founders and investors, LiteFold highlights India's potential to move beyond SaaS into high-value global biotech innovation.
The Take
Everyone is talking LLMs, but the real play here is in verticalized AI platforms solving specific, painful R&D bottlenecks. LiteFold's "IDE for computational biologists" is the kind of sharp tool that delivers outsized returns in deep tech, far beyond generic AI assistants.
Source:
YourStory ↗